Healthcare Analytical Testing Services Market by Type (Biomarker Testing, Stability Testing, Raw Material Testing, Batch-release Testing, Cleaning Validation), End User (Pharmaceutical Companies, Medical Device Companies, CRO) & Region - Global Forecast to 2027
Report Code: AST 4341 Dec, 2022, by marketsandmarkets.com
Updated on : April 19, 2023
The global healthcare analytical testing services market in terms of revenue was estimated to be worth $6.5 billion in 2022 and is poised to reach $11.1 billion by 2027, growing at a CAGR of 11.4% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The shift in focus towards the analytical testing of biologics and biosimilars, the increasing outsourcing of analytical testing by pharmaceutical companies and medical device companies, the increasing number of clinical trials, and the rising acceptance of the QbD approach in pharma research and manufacturing are the major factors driving the growth of the market.
Healthcare Analytical Testing Services Market Opportunities
To know about the assumptions considered for the study, Request for Free Sample Report
Healthcare Analytical Testing Services Market Dynamics
Driver: Growing focus on analytical testing of biologics & biosimilars
Biologics represent one of the most promising new therapeutic areas and are becoming increasingly important in the pharmaceutical market. According to the US FDA 2021 report, in 2021, the Center for Drug Evaluation and Research (CDER) approved 50 new drugs, either as new molecular entities (NMEs) under New Drug Applications (NDAs), or as new therapeutic biologics under Biologics License Applications (BLAs). One of the key reasons for this is the rising prevalence of chronic diseases. Moreover, the introduction of biosimilars and the move toward continuous processing also create the need for more rapid and sensitive analytical techniques.
Restraint: Increasing pressure on market players due to rising cost and market competition
The healthcare analytical testing market is highly competitive and is expected to grow rapidly in the coming years due to the increasing number of bioanalytical CROs. Additionally, the growing number of contract development and manufacturing organizations (CDMOs) offering bioanalytical services is further expected to intensify the competition in the market. In the last few years, the number of bioanalytical testing service providers has increased in emerging markets, such as China, India, and Brazil, which is a major challenge for global players. . Moreover, it could take over six months to complete software validation and full integration with other laboratory systems. This rising cost of bioanalytical testing methods and constantly evolving technologies in this market space pose a challenge to the growth of the healthcare analytical testing services market.
Opportunity: Adoption of new technologies and techniques
Traditionally, pharmaceutical companies outsourced only the late-phase drug development and routine processes to analytical testing service providers and conducted the early-phase method development projects and problem-solving activities in-house. However, pharmaceutical companies are increasingly outsourcing analytical testing programs much earlier in the product development phases to focus on their core therapeutic strengths. For the same reason, most market players are now using advanced equipment such as High-Resolution Accurate Mass Spectrometry (HRAM) instruments, morphologically directed Raman spectroscopy (MDRS), fully validated laboratory information & management systems (LIMS), and harmonized data acquisition applications software to make outsourcing both more efficient and attractive.
Challenge: Need to improve sensitivity of bioanalytical methods
A prominent challenge in this field is ensuring sufficient sensitivity, speed of analysis, and robustness of methodologies. Changes, fluctuations, and variations in end-user demands and regulatory requirements make it highly difficult for service providers to ensure sufficient testing capabilities; they must constantly look for and implement innovative and new assays. Similarly, there are many challenges faced when optimizing bioassays for biologics that increase timelines and exceed budgets, ending in results that do not satisfy requirements. This is because early in the assay development process for biologics, there is limited production experience and incomplete knowledge about assay capabilities. Therefore, developing these analyses is difficult and poorly understood.
The bioanalytical testing services accounted for the largest share in the healthcare analytical testing services market
Based on type, the market is divided into bioanalytical testing, physical characterization, method development and validation, stability testing, batch-release testing, raw material testing, microbial testing, and environmental monitoring services. In 2021, the bioanalytical testing services segment accounted for the largest share of the market. The large share of this segment can be attributed to the availability of comprehensive bioanalytical testing services for a wide range of drug types in the market, including vaccines, small molecules, and biologics, among others.
The cell-based assays segment accounted for the largest share in the healthcare analytical testing services market
Based on type, the market is segmented into cell-based assays, virology testing, biomarker testing, immunogenicity and neutralising antibody testing, pharmacokinetic testing, and other bioanalytical testing services. In 2021, the cell-based assays segment dominated the market. The use of cell-based assays in high-throughput screening has increased due to their ability to provide relevant in vivo biological information in comparison to biochemical assays, which consequently speeds up the process of drug discovery.
The pharmaceutical & biopharmaceutical companies accounted for the largest share in the healthcare analytical testing services market
Based on the end user, the market has been segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and contract research organizations (CROs). Pharmaceutical & biopharmaceutical companies held the largest share in 2021. The large share of this segment is attributed to the increasing outsourcing of analytical testing services by these companies to boost profit margins, and focus on their core business competencies.
North America accounted for the largest share of the healthcare analytical testing services market/h3>
The market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa. North America accounted for the largest share in the market. The large share of this region can primarily be attributed to the rising number of biopharmaceutical and pharmaceutical companies in the US. Moreover, a strong presence of well-established market players in the US is also expected to contribute to the growth of the market.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the healthcare analytical testing services market include Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), SGS S.A. (Switzerland), Charles River Laboratories (US), WuXi AppTec Co. Ltd. (China), PPD, Inc. (US), Element Materials Technology (UK), Thermo Fisher Scientific (US), Pace Analytical Services, LLC. (US), Intertek Group LLC. (UK), Merck KGaA (Germany), Danaher Corporation (US), Source BioScience (UK), Almac Group (UK), ICON plc (Ireland), Frontage Laboratories, Inc. (US), STERIS plc (US), Sartorius AG (Germany), ALS Life Science (US), Syneos Health (US), Medpace Holdings, Inc. (US), Cinven (LGC Limited) (UK), Anacura (Belgium), Impact Analytical (US), & CD BioSciences (US).
Healthcare Analytical Testing Services Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$6.5 billion |
|
Estimated Value by 2027 |
$11.1 billion |
|
Growth Rate |
Poised to grow at a CAGR of 11.4% |
|
Market Segmentation |
Type, End User and Regional Level |
|
Market Driver |
|
|
Market Opportunity |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
The study categorizes the healthcare analytical testing services market into following segments & sub-segments:
By Type
-
Bioanalytical Testing Services
- Cell-Based Assay Services
- Virology Testing Services
- Immunogenicity & Neutralizing Antibody Testing Services
- Biomarker Testing Services
- Pharmacokinetic Testing Services
- Other Bioanalytical Testing Services
-
Physical Characterization Services
- Laser Particle Size Analysis Services
- Thermal Analysis Services
- Image Analysis Services
- Surface Area Analysis Services
- Other Physical Characterization Services
-
Method Development & Validation Testing Services
- Extractables & Leachables Method Development & Validation Services
- Process Impurity Method Development & Validation Services
- Stability-Indicating Method Validation Services
- Cleaning Validation Method Development Services
- Analytical Standard Characterization Services
- Technical Consulting Services
- Other Method Validation Services
-
Raw Material Testing Services
- Complete Compendial Testing Services
- Heavy Metal Testing Services
- Container Testing Services
- Karl Fischer Analysis Services
- Wet Chemistry Analysis Services
- Other Raw Material Testing Services
-
Batch-Release Testing Services
- Dissolution Testing Services
- Elemental Impurity Testing Services
- Disintegration Testing Services
- Hardness Testing Services
- Friability Testing Services
- Other Batch-Release Testing Services
-
Stability Testing
- Drug Substance Stability Testing Services
- Formulation Evaluation Stability Testing Services
- Accelerated Stability Testing Services
- Photostability Testing Services
- Comparative Stability Testing Services
- Other Stability Testing Services
-
Microbial Testing Services
- Microbial Limit Testing Services
- Sterility Testing Services
- Endotoxin Testing Services
- Preservative Efficacy Testing Services
- Water Testing Services
- Other Microbial Testing Services
-
Environmental Monitoring Services
- Air Testing Services
- Wastewater/ETP Testing Services
- Other Environmental Monitoring Services
By End User
- Pharmaceutical & Biopharmaceutical Companies
- Medical Device Companies
- Clinical Research Organizations
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Switzerland
- Rest Of Europe (RoE)
-
Asia Pacific (APAC)
- China
- Japan
- India
- South Korea
- Australia
- Rest Of APAC
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
Recent Developments:
- In July 2022, LabCorp (US) partnered with MD Anderson Cancer Center Foundation to accelerate new discoveries and development of cancer therapies worldwide. It also aims to meet the growing demand for and access to early-phase oncology clinical trials throughout Spain.
- In March 2022, WuXi Advanced Therapies (WuXi ATU) launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA). To ensure stable gene therapy production, the novel TESSA technology is integrated with intricate testing capabilities
- In July 2022, SGS acquired Silver State Analytical and Excelchem to expand its environmental testing capabilities in western US. This was also a part of SGS Group’s global strategy for the Industries & Environment sector
- In March 2022, Thermo Fisher (US) collaborated with Symphogen (US) to provide biopharmaceutical discovery and development laboratories with innovative tools and streamlined workflows for efficient characterization of complex therapeutic proteins.
- In April 2021, Charles River Laboratories (US) acquired Retrogenix Ltd. (UK), which provides air sampling and quality and offers cell microarray services, to boost its early-stage contract research organization offerings.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global healthcare analytical testing services market?
The global healthcare analytical testing services market boasts a total revenue value of $11.1 billion by 2027.
What is the estimated growth rate (CAGR) of the global healthcare analytical testing services market?
The global market for healthcare analytical testing services has an estimated compound annual growth rate (CAGR) of 11.4% and a revenue size in the region of $6.5 billion in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 47)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKETS COVERED
FIGURE 1 MARKET SEGMENTATION
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
TABLE 1 USD EXCHANGE RATES CONSIDERED, 2018–2021
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 52)
2.1 RESEARCH APPROACH
FIGURE 2 MARKET: RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 11 CAGR PROJECTIONS
2.3 DATA TRIANGULATION APPROACH
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
3 EXECUTIVE SUMMARY (Page No. - 65)
FIGURE 13 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 14 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 15 PHYSICAL CHARACTERIZATION TESTING SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 16 MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 70)
4.1 MARKET OVERVIEW
FIGURE 18 GROWING ADOPTION OF OUTSOURCED ANALYTICAL TESTING SERVICES BY PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES TO DRIVE GROWTH
4.2 EUROPE: MARKET, BY TYPE AND COUNTRY (2021)
FIGURE 19 BIOANALYTICAL TESTING SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 REGIONAL MIX: MARKET (2020–2027)
FIGURE 21 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD (2020–2027)
4.5 MARKET: DEVELOPED VS. DEVELOPING MARKETS (2022 VS. 2027)
FIGURE 22 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 74)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing focus on analytical testing of biologics & biosimilars
TABLE 3 PATENT EXPIRY OF BEST-SELLING BIOLOGICS
5.2.1.2 Increasing outsourcing of analytical testing by pharmaceutical and medical device companies
5.2.1.3 Increasing number of clinical trials
FIGURE 24 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2002–2021)
5.2.1.4 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
FIGURE 25 PHARMACEUTICAL & BIOPHARMACEUTICAL R&D EXPENDITURE, 2001–2021
5.2.1.5 Rising acceptance of quality-by-design approach in pharma research and manufacturing
TABLE 4 IMPACT ANALYSIS: DRIVERS
5.2.2 RESTRAINTS
5.2.2.1 Shortage of skilled professionals
5.2.2.2 Increasing pressure on market players due to rising costs and market competition
TABLE 5 IMPACT ANALYSIS: RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of new techniques and technologies
5.2.3.2 Growing focus on emerging markets
TABLE 6 IMPACT ANALYSIS: OPPORTUNITIES
5.2.4 CHALLENGES
5.2.4.1 Specific requirements for innovative formulations and medical devices
5.2.4.2 Need to improve sensitivity of bioanalytical methods
TABLE 7 IMPACT ANALYSIS: CHALLENGES
5.3 KEY CONFERENCES & EVENTS, 2022–2023
TABLE 8 HEALTHCARE ANALYTICAL TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.4 INDUSTRY TRENDS
5.4.1 EXPANDING SERVICE PORTFOLIO AND MARKET REACH THROUGH ACQUISITIONS
TABLE 9 MAJOR ACQUISITIONS IN GLOBAL MARKET
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 10 PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT FROM NEW ENTRANTS
5.5.2 BARGAINING POWER OF SUPPLIERS
5.5.3 INTENSITY OF COMPETITIVE RIVALRY
5.5.4 BARGAINING POWER OF BUYERS
5.5.5 THREAT FROM SUBSTITUTES
5.6 KEY STAKEHOLDERS & BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.6.2 BUYING CRITERIA
TABLE 12 KEY BUYING CRITERIA FOR END USERS
5.7 CASE STUDY ANALYSIS
5.7.1 CASE STUDY 1: WELLSTAT THERAPEUTICS & ALMAC GROUP
5.7.2 CASE STUDY 2: METHOD DEVELOPMENT CASE STUDY
5.8 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 REGULATORY ANALYSIS
TABLE 14 ICH QUALITY GUIDELINES FOR PHARMACEUTICAL GMPS
TABLE 15 OVERVIEW OF GUIDELINES OF LABORATORY SERVICES
5.9.1 NORTH AMERICA
5.9.2 EUROPE
TABLE 16 DEVELOPMENT OF GLP ACROSS COUNTRIES
TABLE 17 REGULATORY AUTHORITIES AND LAUNCH OF GLP MONITORING PROGRAMS IN EUROPEAN COUNTRIES
5.9.3 ASIA PACIFIC
5.10 TECHNOLOGY ANALYSIS
5.10.1 LIMS (LABORATORY INFORMATION MANAGEMENT SYSTEMS) PLATFORMS
5.10.2 INTACT MOLECULAR WEIGHT BY MASS SPECTROMETRY
5.10.3 MULTI-ATTRIBUTE METHODS BASED ON PEPTIDE MAPPING BY LC-UV-MS
5.10.4 TETRACYCLINE-ENABLED SELF-SILENCING ADENOVIRUS (TESSA)
5.11 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS
FIGURE 28 VALUE CHAIN ANALYSIS: DRUG DEVELOPMENT & MANUFACTURING PROCESS
5.12 ECOSYSTEM ANALYSIS
TABLE 18 MARKET: ECOSYSTEM
5.13 PATENT ANALYSIS: BIOANALYTICAL TESTING
5.13.1 PATENT PUBLICATION TRENDS FOR BIOANALYTICAL TESTING
FIGURE 29 PATENT PUBLICATION TRENDS (2011–OCTOBER 2022)
5.13.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 30 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR BIOANALYTICAL TESTING (JANUARY 2011–OCTOBER 2022)
FIGURE 31 TOP APPLICANT JURISDICTIONS FOR BIOANALYTICAL TESTING PATENTS (JANUARY 2011–OCTOBER 2022)
TABLE 19 LIST OF PATENTS/PATENT APPLICATIONS IN BIOANALYTICAL TESTING MARKET, 2021–2022
6 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE (Page No. - 100)
6.1 INTRODUCTION
TABLE 20 MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 BIOANALYTICAL TESTING SERVICES
TABLE 21 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 22 BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 CELL-BASED ASSAYS
6.2.1.1 Growing adoption of high-content screening for cytotoxicity testing to fuel growth
TABLE 23 CELL-BASED ASSAY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 VIROLOGY TESTING
6.2.2.1 Increasing outbreaks of viral diseases to drive market
TABLE 24 VIROLOGY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING
6.2.3.1 Increasing requirement for drug safety approvals to support market
TABLE 25 IMMUNOGENICITY & NEUTRALIZING ANTIBODY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.4 BIOMARKER TESTING
6.2.4.1 Rising need for specialized drug development to drive market
TABLE 26 BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.5 PHARMACOKINETIC TESTING
6.2.5.1 Increasing number of clinical trials for drug development to propel growth
TABLE 27 PHARMACOKINETIC TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.6 OTHER BIOANALYTICAL TESTING SERVICES
TABLE 28 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 PHYSICAL CHARACTERIZATION
TABLE 29 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 30 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.1 LASER PARTICLE SIZE ANALYSIS
6.3.1.1 Growing importance of particle size analysis in manufacturing pharmaceutical dosage forms to drive market
TABLE 31 LASER PARTICLE SIZE ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 THERMAL ANALYSIS
6.3.2.1 Advancements in thermal analysis techniques to support growth
TABLE 32 THERMAL ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3 IMAGE ANALYSIS
6.3.3.1 Growing complexity of biological structures to contribute to growth
TABLE 33 IMAGE ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4 SURFACE AREA ANALYSIS
6.3.4.1 Growing need of surface analysis to streamline drug development processes to fuel growth
TABLE 34 SURFACE AREA ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.5 OTHER PHYSICAL CHARACTERIZATION ANALYSIS SERVICES
TABLE 35 OTHER PHYSICAL CHARACTERIZATION ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 METHOD DEVELOPMENT & VALIDATION
TABLE 36 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 37 METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.1 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION
6.4.1.1 Growing development of parenterally administered drugs and biologic products to drive market
TABLE 38 EXTRACTABLES/LEACHABLES METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.2 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION
6.4.2.1 Rising emphasis on impurity testing to boost market
TABLE 39 PROCESS IMPURITY METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.3 STABILITY-INDICATING METHOD VALIDATION
6.4.3.1 Need to ensure safety and efficacy of therapeutic drugs to spur growth
TABLE 40 STABILITY-INDICATING METHOD VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.4 CLEANING VALIDATION
6.4.4.1 Growing need to evaluate cleaning practices and ensure complete decontamination to fuel growth
TABLE 41 CLEANING VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.5 ANALYTICAL STANDARD CHARACTERIZATION
6.4.5.1 Growing importance of analytical standard characterization in drug development to support market
TABLE 42 ANALYTICAL STANDARD CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.6 TECHNICAL CONSULTING
6.4.6.1 Need for regulatory approvals for drug development to drive market
TABLE 43 TECHNICAL CONSULTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.4.7 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES
TABLE 44 OTHER METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5 RAW MATERIAL TESTING
TABLE 45 RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 46 RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.1 COMPLETE COMPENDIAL TESTING
6.5.1.1 Need to determine efficacy and safety of therapeutic products to drive growth
TABLE 47 COMPLETE COMPENDIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.2 CONTAINER TESTING
6.5.2.1 Need to optimize sealing and evaluate temperature impact to fuel growth
TABLE 48 CONTAINER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.3 HEAVY METAL TESTING
6.5.3.1 Implementation of various techniques and technologies for heavy metal testing to aid growth
TABLE 49 HEAVY METAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.4 KARL FISCHER ANALYSIS
6.5.4.1 Need to check for water content in pharmaceutical products to support growth
TABLE 50 KARL FISCHER ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.5 WET CHEMISTRY ANALYSIS
6.5.5.1 Adoption of upcoming technologies to boost market
TABLE 51 WET CHEMISTRY ANALYSIS SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.5.6 OTHER RAW MATERIAL TESTING SERVICES
TABLE 52 OTHER RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6 BATCH-RELEASE TESTING SERVICES
TABLE 53 BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 54 BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6.1 DISSOLUTION TESTING
6.6.1.1 Wide usage of dissolution testing in formulation development and manufacturing to drive growth
TABLE 55 DISSOLUTION TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6.2 ELEMENTAL IMPURITY TESTING
6.6.2.1 Need to minimize cost of in-house analysis and labor to fuel growth
TABLE 56 ELEMENTAL IMPURITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6.3 DISINTEGRATION TESTING
6.6.3.1 Need to ensure batch-to-batch consistency of pharmaceutical dosage forms to promote growth
TABLE 57 BREAKDOWN OF DISINTEGRATION METHODS AND IMMERSION MEDIA
TABLE 58 DISINTEGRATION TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6.4 HARDNESS TESTING
6.6.4.1 Need to assess manufacturability and compactness of pharmaceutical formulations to ensure growth
TABLE 59 HARDNESS TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6.5 FRIABILITY TESTING
6.6.5.1 Need to measure resistance of TABLEts and granules to abrasion to support market
TABLE 60 FRIABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.6.6 OTHER BATCH-RELEASE TESTING SERVICES
TABLE 61 OTHER BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7 STABILITY TESTING
TABLE 62 STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 63 STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7.1 DRUG SUBSTANCE STABILITY TESTING
6.7.1.1 Regulatory requirements for drug approval to drive market
TABLE 64 DRUG SUBSTANCE STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7.2 FORMULATION EVALUATION STABILITY TESTING
6.7.2.1 Need to analyze and predict shelf life of products to drive demand
TABLE 65 FORMULATION EVALUATION STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7.3 ACCELERATED STABILITY TESTING
6.7.3.1 Growing use of accelerated stability testing to determine shelf life of pharmaceutical products to fuel growth
TABLE 66 ACCELERATED STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7.4 PHOTOSTABILITY TESTING
6.7.4.1 Need for robust photostability testing process to ensure product quality and safety to drive adoption
TABLE 67 PHOTOSTABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7.5 COMPARATOR STABILITY TESTING
6.7.5.1 Need to assess relative bioequivalence, efficacy, and safety of products to boost market
TABLE 68 COMPARATOR STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.7.6 OTHER STABILITY TESTING SERVICES
TABLE 69 OTHER STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8 MICROBIAL TESTING
TABLE 70 MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 MICROBIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.1 MICROBIAL LIMIT TESTING
6.8.1.1 Need to determine whether products comply with compendial specifications for microbial quality to boost adoption
TABLE 72 STANDARD LIMITS FOR MICROBIAL LIMIT TESTING
TABLE 73 MICROBIAL LIMIT TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.2 STERILITY TESTING
6.8.2.1 Rising development of parenteral preparations and immunological products to drive market
TABLE 74 STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.3 ENDOTOXIN TESTING
6.8.3.1 Need to standardize procedures and follow regulatory guidelines to support demand
TABLE 75 ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.4 PRESERVATIVE EFFICACY TESTING
6.8.4.1 Need to ensure product safety for product approval to support growth
TABLE 76 PRESERVATIVE EFFICACY TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.5 WATER TESTING
6.8.5.1 Growing development of pharmaceutical drugs to drive market
TABLE 77 STANDARDIZED LIMITS FOR WATER TESTING
TABLE 78 WATER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.8.6 OTHER MICROBIAL TESTING SERVICES
TABLE 79 OTHER MICROBIAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.9 ENVIRONMENTAL MONITORING SERVICES
TABLE 80 ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.9.1 AIR TESTING
6.9.1.1 Need to ensure safe environment for healthcare product development to drive market
TABLE 82 PURITY CLASSES FOR PARTICLES, WATER, AND OIL IN COMPRESSED AIR
TABLE 83 AIR TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.9.2 WASTEWATER TESTING SERVICES
6.9.2.1 Need to minimize water contamination to support demand
TABLE 84 STANDARDS FOR WASTEWATER QUALITY
TABLE 85 WASTEWATER TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.9.3 OTHER ENVIRONMENTAL MONITORING SERVICES
TABLE 86 OTHER ENVIRONMENTAL MONITORING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY END USER (Page No. - 176)
7.1 INTRODUCTION
TABLE 87 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
7.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
7.2.1 INCREASED OUTSOURCING OF R&D ACTIVITIES TO DRIVE MARKET GROWTH
FIGURE 32 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2019–2021
TABLE 88 GLOBAL MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 MEDICAL DEVICE COMPANIES
7.3.1 STRICT APPROVAL NORMS FOR MEDICAL DEVICES TO SUPPORT GROWTH
TABLE 89 GLOBAL MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 CONTRACT RESEARCH ORGANIZATIONS
7.4.1 GROWING NUMBER OF CLINICAL TRIALS TO BOOST MARKET
TABLE 90 GLOBAL MARKET FOR CROS, BY COUNTRY, 2020–2027 (USD MILLION)
8 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION (Page No. - 183)
8.1 INTRODUCTION
FIGURE 33 GLOBAL MARKET: GEOGRAPHIC SNAPSHOT (2021)
TABLE 91 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 34 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA (2019)
FIGURE 35 NORTH AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET
TABLE 92 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 94 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 NORTH AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.1 US
8.2.1.1 High number of pre-registration drugs in pipeline to drive market
FIGURE 36 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019)
TABLE 103 US: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 US: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 US: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 US: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 US: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 US: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 US: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 110 US: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 111 US: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Well-established CROs to support market growth
TABLE 113 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2020)
TABLE 114 CANADA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 CANADA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 CANADA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 CANADA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 CANADA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 119 CANADA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 CANADA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 CANADA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 CANADA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 123 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3 EUROPE
TABLE 124 EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 125 EUROPE: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 126 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 129 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 130 EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 132 EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133 EUROPE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Government support and flexible labor laws to make Germany favorable location for clinical trials
TABLE 135 GERMANY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 GERMANY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 GERMANY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 GERMANY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 GERMANY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 GERMANY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 141 GERMANY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 142 GERMANY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 GERMANY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 144 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.2 FRANCE
8.3.2.1 Government regulations in France to drive market
TABLE 145 FRANCE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 FRANCE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 147 FRANCE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148 FRANCE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149 FRANCE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 FRANCE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 151 FRANCE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 FRANCE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 FRANCE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 154 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.3 UK
8.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to support growth
TABLE 155 UK: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 UK: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 UK: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 UK: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 UK: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 160 UK: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 161 UK: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 UK: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 UK: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 164 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Low drug approval time in Italy to drive growth
TABLE 165 ITALY: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 166 ITALY: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 ITALY: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 ITALY: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169 ITALY: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 170 ITALY: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 171 ITALY: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 172 ITALY: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 173 ITALY: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.5 SWITZERLAND
8.3.5.1 Large and growing pharma production volume to drive demand for analytical testing services
TABLE 175 SWITZERLAND: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 176 SWITZERLAND: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 SWITZERLAND: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 178 SWITZERLAND: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 179 SWITZERLAND: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 180 SWITZERLAND: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 181 SWITZERLAND: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 182 SWITZERLAND: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183 SWITZERLAND: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 SWITZERLAND: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.6 SPAIN
8.3.6.1 Rising R&D expenditure to boost growth
TABLE 185 SPAIN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 186 SPAIN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 SPAIN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 SPAIN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189 SPAIN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 190 SPAIN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 191 SPAIN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 192 SPAIN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 193 SPAIN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 194 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.3.7 REST OF EUROPE (ROE)
TABLE 195 REST OF EUROPE: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 196 REST OF EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 REST OF EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 REST OF EUROPE: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 199 REST OF EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 200 REST OF EUROPE: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 201 REST OF EUROPE: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 202 REST OF EUROPE: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 REST OF EUROPE: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 204 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4 ASIA PACIFIC (APAC)
FIGURE 37 ASIA PACIFIC: HEALTHCARE ANALYTICS TESTING SERVICES MARKET SNAPSHOT
TABLE 205 ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 206 ASIA PACIFIC: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 207 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209 ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 210 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 211 ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 212 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 214 ASIA PACIFIC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 215 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.1 CHINA
8.4.1.1 Low manufacturing cost of medicines to drive demand
TABLE 216 CHINA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 217 CHINA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 CHINA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219 CHINA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220 CHINA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 221 CHINA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 222 CHINA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 223 CHINA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 224 CHINA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 225 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.2 JAPAN
8.4.2.1 Rising geriatric population to support market
TABLE 226 JAPAN: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 227 JAPAN: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 JAPAN: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 229 JAPAN: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 230 JAPAN: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 231 JAPAN: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 232 JAPAN: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 233 JAPAN: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234 JAPAN: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 235 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Increasing number of clinical trials to drive market growth
TABLE 236 INDIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 237 INDIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 INDIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 239 INDIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 240 INDIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 241 INDIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 242 INDIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 243 INDIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244 INDIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 245 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.4 AUSTRALIA
8.4.4.1 Large number of research institutes to make Australia favorable location for drug discovery
TABLE 246 AUSTRALIA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 247 AUSTRALIA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 AUSTRALIA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 249 AUSTRALIA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 250 AUSTRALIA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 251 AUSTRALIA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 252 AUSTRALIA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 253 AUSTRALIA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 254 AUSTRALIA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 255 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.5 SOUTH KOREA
8.4.5.1 Growth in clinical trial activity to propel growth
TABLE 256 SOUTH KOREA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 257 SOUTH KOREA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 258 SOUTH KOREA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 SOUTH KOREA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 260 SOUTH KOREA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 261 SOUTH KOREA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 262 SOUTH KOREA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 263 SOUTH KOREA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 264 SOUTH KOREA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 265 SOUTH KOREA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.4.6 REST OF ASIA PACIFIC (ROAPAC)
TABLE 266 REST OF ASIA PACIFIC: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 267 REST OF ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 268 REST OF ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 REST OF ASIA PACIFIC: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 270 REST OF ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 271 REST OF ASIA PACIFIC: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 272 REST OF ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 273 REST OF ASIA PACIFIC: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 274 REST OF ASIA PACIFIC: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 275 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.5 LATIN AMERICA
TABLE 276 LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 277 LATIN AMERICA: MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 280 LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 281 LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 282 LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 283 LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 284 LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 285 LATIN AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 286 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.5.1 BRAZIL
8.5.1.1 Rising adoption of emerging medical technologies to drive market
TABLE 287 BRAZIL: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 288 BRAZIL: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 289 BRAZIL: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290 BRAZIL: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 291 BRAZIL: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 292 BRAZIL: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 293 BRAZIL: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 294 BRAZIL: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 295 BRAZIL: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 296 BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.5.2 MEXICO
8.5.2.1 Government initiatives and robust supply to drive market
TABLE 297 MEXICO: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 298 MEXICO: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 299 MEXICO: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 300 MEXICO: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 301 MEXICO: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 302 MEXICO: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 303 MEXICO: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 304 MEXICO: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 305 MEXICO: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 306 MEXICO: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.5.3 REST OF LATIN AMERICA
TABLE 307 REST OF LATIN AMERICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 308 REST OF LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 309 REST OF LATIN AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 310 REST OF LATIN AMERICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311 REST OF LATIN AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 312 REST OF LATIN AMERICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 313 REST OF LATIN AMERICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 314 REST OF LATIN AMERICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 315 REST OF LATIN AMERICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 316 REST OF LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 INCREASING INVESTMENT OPPORTUNITIES FOR DOMESTIC MANUFACTURING OF MEDICAL DEVICES TO DRIVE GROWTH
TABLE 317 MIDDLE EAST & AFRICA: HEALTHCARE ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 318 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 319 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 320 MIDDLE EAST & AFRICA: METHOD DEVELOPMENT & VALIDATION SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 321 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 322 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 323 MIDDLE EAST & AFRICA: STABILITY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 324 MIDDLE EAST & AFRICA: MICROBIAL TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 325 MIDDLE EAST & AFRICA: ENVIRONMENTAL MONITORING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 326 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
9 COMPETITIVE LANDSCAPE (Page No. - 316)
9.1 INTRODUCTION
9.2 STRATEGIES ADOPTED BY KEY PLAYERS
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
9.3 REVENUE SHARE ANALYSIS
FIGURE 38 REVENUE ANALYSIS FOR KEY PLAYERS, 2016–2021
9.4 MARKET SHARE ANALYSIS
FIGURE 39 HEALTHCARE ANALYTICAL TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2021
TABLE 327 GLOBAL MARKET: DEGREE OF COMPETITION
9.5 COMPANY EVALUATION QUADRANT
9.5.1 STARS
9.5.2 PERVASIVE PLAYERS
9.5.3 EMERGING LEADERS
9.5.4 PARTICIPANTS
FIGURE 40 GLOBAL MARKET: COMPANY EVALUATION QUADRANT (2021)
9.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS (2021)
9.6.1 PROGRESSIVE COMPANIES
9.6.2 DYNAMIC COMPANIES
9.6.3 STARTING BLOCKS
9.6.4 RESPONSIVE COMPANIES
FIGURE 41 GLOBAL MARKET: SME/START-UP COMPANY EVALUATION MATRIX, 2021
9.7 COMPETITIVE BENCHMARKING
TABLE 328 GLOBAL MARKET: DETAILED LIST OF SMALL & MEDIUM-SIZED PLAYERS
9.8 COMPANY FOOTPRINT
TABLE 329 COMPANY FOOTPRINT (20 COMPANIES)
TABLE 330 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
TABLE 331 COMPANY END-USER FOOTPRINT (20 COMPANIES)
TABLE 332 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
9.9 COMPETITIVE SITUATIONS AND TRENDS
9.9.1 SERVICE LAUNCHES & APPROVALS
TABLE 333 SERVICE LAUNCHES (2019–OCTOBER 2022)
9.9.2 DEALS
TABLE 334 DEALS (2019–OCTOBER 2022)
TABLE 335 OTHER DEVELOPMENTS (2019–OCTOBER 2022)
10 COMPANY PROFILES (Page No. - 332)
(Business Overview, Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS
10.1.1 EUROFINS SCIENTIFIC
FIGURE 42 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021)
10.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
FIGURE 43 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2021)
10.1.3 WUXI APPTEC
FIGURE 44 WUXI APPTEC: COMPANY SNAPSHOT (2021)
10.1.4 CHARLES RIVER LABORATORIES
FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)
10.1.5 SGS S.A.
FIGURE 46 SGS S.A.: COMPANY SNAPSHOT (2021)
10.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 341 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
10.1.7 MEDPACE HOLDINGS
FIGURE 48 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2021)
10.1.8 SARTORIUS AG
TABLE 343 SARTORIUS AG: BUSINESS OVERVIEW
FIGURE 49 SARTORIUS AG: COMPANY SNAPSHOT (2021)
10.1.9 INTERTEK GROUP PLC
TABLE 344 INTERTEK GROUP PLC: BUSINESS OVERVIEW
FIGURE 50 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021)
10.1.10 MERCK KGAA
TABLE 345 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 51 MERCK KGAA: COMPANY SNAPSHOT (2021)
10.1.11 SOURCE BIOSCIENCE
TABLE 346 SOURCE BIOSCIENCE: BUSINESS OVERVIEW
FIGURE 52 SOURCE BIOSCIENCE: COMPANY SNAPSHOT (2021)
10.1.12 ICON PLC
TABLE 347 ICON PLC: BUSINESS OVERVIEW
FIGURE 53 ICON PLC: COMPANY SNAPSHOT (2021)
10.1.13 ALS LIFE SCIENCES
TABLE 348 ALS LIFE SCIENCES: BUSINESS OVERVIEW
FIGURE 54 ALS LIFE SCIENCES: COMPANY SNAPSHOT (2022)
10.1.14 FRONTAGE LABORATORIES, INC.
TABLE 349 FRONTAGE LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 55 FRONTAGE LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
10.1.15 STERIS PLC
TABLE 350 STERIS PLC: BUSINESS OVERVIEW
FIGURE 56 STERIS PLC: COMPANY SNAPSHOT (2022)
10.1.16 IQVIA INC.
FIGURE 57 IQVIA: COMPANY SNAPSHOT (2021)
10.1.17 ELEMENT MATERIALS TECHNOLOGY
TABLE 352 ELEMENT MATERIALS TECHNOLOGY: BUSINESS OVERVIEW
10.1.18 PACE ANALYTICAL SERVICES
TABLE 353 PACE ANALYTICAL SERVICES: BUSINESS OVERVIEW
10.1.19 ALMAC GROUP
TABLE 354 ALMAC GROUP: BUSINESS OVERVIEW
10.1.20 ABSORPTION SYSTEMS
TABLE 355 ABSORPTION SYSTEMS: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 SYNEOS HEALTH INC.
10.2.2 PAREXEL INTERNATIONAL CORPORATION
10.2.3 LGC LIMITED
10.2.4 CELERION
10.2.5 BIOAGILYTIX LABS
*Details on Business Overview, Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 403)
11.1 INSIGHTS FROM INDUSTRY EXPERTS
11.2 DISCUSSION GUIDE
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.4 CUSTOMIZATION OPTIONS
11.5 RELATED REPORTS
11.6 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and company house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global healthcare analytical testing services market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply side and other participants were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, presidents, vice presidents, directors, marketing directors, marketing managers, and related executives from various key companies and organizations in the healthcare analytical testing services industry. The primary sources from the other participants group including pharmaceutical and biopharmaceutical manufacturers, C-level executives, department heads, medical device manufacturers, and personnel from CROs. And others including, private consultants, suppliers, distributers and officials from government regulatory bodies.
A breakdown of the primary respondents is provided below:
*Others include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue, as of 2021: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by type, end user, and region).
Data Triangulation
After arriving at the market size, the total healthcare analytical testing services market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.
Objectives of the Study
- To define, describe, segment, and forecast the healthcare analytical testing service market by type, end user, and by region.
- To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall healthcare analytical testing services market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market in five main regions (along with their respective key countries), namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the healthcare analytical testing services market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, FDA approvals, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the market
- To benchmark players within the healthcare analytical testing services market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and service offering
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Geographic Analysis
- Further breakdown of the Rest of Europe healthcare analytical testing services market into Belgium, Russia, and the Netherlands
- Further breakdown of the Middle East healthcare analytical testing services market into Saudi Arabia, and others.
Generating Response ...
Growth opportunities and latent adjacency in Healthcare Analytical Testing Services Market